Human papillomaviruses vaccine: A dermatologic perspective

Indian Journal of Dermatology, Venereology and Leprology

Volumn 76, Issue 1, 2010, Pages 14-19

  Satyaprakash, Anita K ^a   Tyring, Stephen K ^a  

^a CENTER FOR CLINICAL STUDIES   (United States)

Author keywords

Anogenital warts; Cervical cancer; Human papillomavirus; Vaccines

Indexed keywords

WART VIRUS VACCINE;

CONDYLOMA ACUMINATUM; HUMAN; INDIA; INFECTION RISK; MIXED INFECTION; REVIEW; UTERINE CERVIX CANCER; VACCINATION; WART VIRUS;

ANIMALS; CONDYLOMATA ACUMINATA; DERMATOLOGIC AGENTS; FEMALE; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS;

EID: 77949908169     PISSN: 03786323     EISSN: 09733922     Source Type: Journal    
DOI: 10.4103/0378-6323.58673     Document Type: Review

References (29)

1. Gunter J. Genital and perianal warts: New treatment opportunities for human papillomavirus infection. Am J Obstet Gynecol 2003;189: S3-11.
2. Parkin DM, Bray F. Chapter 2: The burden of HPV-related cancers. Vaccine 2006;24:11-25.
3. WHO/ICO Information Centre on HPV and Cervical Cancer. Summary report on HPV and cervical cancer statistics in India, 2007. Available from: Www.who.int/hpvcentre. [last accessed on Aug 4,2008]
4. Das BC, Hussain S, Nasare V, Bharadwaj M. Prospects and prejudices of human papillomavirus vaccines in India. Vaccine 2008;26:2669-2679
5. Stewart BW, editor. World Cancer Report. Lyon, France: IARC Press, 2003.
6. Lacey CJ. Therapy for genital human papillomavirus-related disease. J Clin Virol 2005;32: S82-90.
7. Bryan JT. Developing an HPV vaccine to prevent cervical cancer and genital warts. Vaccine 2007;25:3001-3006
8. IARC. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, in Human Papillomaviruses. Lyon, France: IARC Press, 2005.
9. Thappa DM, Senthilkumar M, Laxmisha C. Anogenital warts-an overview. Indian J Sex Transm Dis 2004;25:55-66.
10. Bleeker MC, Hogewoning CJ, Voorhorst FJ, van den Brule AJ, Berkhof J, Hesselink AT, et al. HPV-associated flat penile lesions in men of a non-STD hospital population: Less frequent and smaller in size than in male sexual partners of women with CIN. Int J Cancer 2005;113:36-41.
11. Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518-527
12. Clifford G, Franceschi S, Diaz M, Muñoz N, Villa LL. Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine 2006;24:26-34.
13. Trimble CL, Hildesheim A, Brinton LA, Shah KV, Kurman RJ. Heterogeneous etiology of squamous carcinoma of the vulva. Obstet Gynecol 1996;87:59-64.
14. Daling JR, Madeleine MM, Johnson LG, Schwartz SM, Shera KA, Wurscher MA, et al. Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer. Cancer 2004;101:270-280
15. Frisch M, Fenger C, van den Brule AJ, Sørensen P, Meijer CJ, Walboomers JM, et al. Variants of Squamous Cell Carcinoma of the Anal Canal and Perianal Skin and Their Relation to Human Papillomaviruses. Cancer Res 1999;59:753-757
16. Barnes LE, Reichart JW, Sidransky P, editors. World Health Organization Classification of Tumors. Pathology and Genetics of Head and Neck Tumors. Lyon, France: IARC Press, 2005.
17. Gewirtzman A, Bartlett B, Tyring S. Epidermodysplasia verruciformis and human papilloma virus. Curr Opin Infect Dis 2008;21:141-146
18. Wheeler CM. Advances in primary and secondary interventions for cervical cancer: Human papillomavirus prophylactic vaccines and testing. Nat Clin Pract Oncol 2007;4:224-235
19. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007;356:1928-1943
20. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007;356:1915-1927
21. Villa LL, Costa RL, Petta CA, Andrade RP, Paavonen J, Iversen OE, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 viruslike particle vaccine through 5 years of follow-up. Br J Cancer 2006;95:1459-1466
22. Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, et al. Efficacy of a Bivalent L1 Virus-Like Particle Vaccine in Prevention of Infection With Human Papillomavirus Types 16 and 18 in Young Women: A Randomized Trial. Lancet 2004;364:1757-1765
23. Agarwal SS, Sehgal A, Sardana S, Kumar A, Luthra UK. Role of Male Behavior in Cervical Carcinogenesis among Women with One Lifetime Sexual Partner. Cancer 1993;72:1666-1669
24. Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER, et al. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep 2007;56:16-18
25. American Academy of Pediatrics, Committee on Infectious Diseases. Prevention of Human Papillomavirus Infection: Provisional Recommendations for Immunization of Females with Quadrivalent Human Papillomavirus Vaccine- United States, 2007. Available from: http://pediatrics. aappublications.org/cgi/ content/full/120/3/666. [last accessed on Aug 4,2008]
26. Bayas JM, Costas L, Muñoz A. Cervical cancer vaccination indications, efficacy, and side effects. Gynecol Oncol 2008;110: S11-4.
27. Indian Academy of Pediatrics, Committee on Immunization. Consensus recommendations on immunization, 2008. Indian Pedatrics 2008;45:635-648
28. Kane MA, Sherris J, Coursaget P, Aguado T, Cutts F. Chapter 15: HPV vaccine use in the developing world. Vaccine 2006;24:132-139
29. Cohen J. Public health: High hopes and dilemmas for a cervical cancer vaccine. Science 2005;308:618-621